BMC Ophthalmology · 10 authors, 3 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This study protocol outlines a prospective investigation to test if polygenic risk scores can effectively stratify risk for glaucoma and age-related macular degeneration in a general population. The central plan is to compare the prevalence of these eye diseases between individuals with low, intermediate, and high genetic risk scores.
The GRADE study is a prospective protocol designed to assess the clinical validity of polygenic risk scores (PRS) for stratifying the risk of glaucoma and age-related macular degeneration (AMD) in the general population. The methods plan to recruit 1000 individuals aged over 50, genotype them, and calculate a PRS for each condition. A subset of participants from the low, intermediate, and high PRS groups will undergo detailed eye examinations. The primary objective is to compare the prevalence of glaucoma and AMD across these risk groups, with the expectation of finding higher prevalence in the high PRS group. The protocol identifies key limitations, including that current PRS models are primarily validated in European populations, which may reduce prediction accuracy for other ancestries. The study aims to provide foundational evidence for integrating PRS into clinical practice to enable earlier detection and intervention, potentially preventing unnecessary vision loss.
